Just a few weeks into the full-scale rollout of its Omnipod 5 insulin pump, Insulet has gotten the green light to expand the device’s reach even further. When the FDA originally cleared the automated, ...
2022 is the year of the Omnipod 5 for Insulet. The year kicked off with FDA clearance for the latest generation of the insulin pump—which is tubeless, fully wearable and can be completely controlled ...
The FDA cleared an updated algorithm for a hybrid closed-loop insulin delivery system that permits users to set a lower ...
The Omnipod 5 will be immediately available for people ages 6 to 70. A new technology for people with Type 1 diabetes, one that has been nearly a decade in the making, has been approved by the U.S.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...
As a child with Type 1 diabetes, Arden Benner of Robbinsville, New Jersey, has gotten used to needle sticks and injections. Scott Benner, her father, says, "21 injections every 3 days, plus her finger ...
OAKVILLE, ON, April 7, 2025 /CNW/ - Insulet Corporation (PODD), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Omnipod 5 is now ...
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...
Insulet Corporation’s PODD Omnipod and Omnipod DASH insulin management systems recently received FDA’s approval for their use with Eli Lilly and Company’s LLY Lyumjev (insulin lispro-aabc injection) ...
Insulet delivered third-quarter revenue growth of 25% in constant currency and pushed up gross margin by 150 basis points after a savvy decision to consolidate all pumps to the Omnipod 5 platform. Why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results